Lichtenfeld’s “Genesis Cure” — “This single technology could wipe 4,800 incurable diseases off the face of the Earth”

What's Lightning Trend Trader's pitch about? They say "revenue could soar a mind-blowing 303,316% over time starting November 1st"

By Travis Johnson, Stock Gumshoe, August 30, 2017

Fear Of Missing Out is such a big deal that it gets its own acronym in my book (FOMO — and a clever FOMO-fueling website here), and it drives investors to take huge chances just so they don’t have to worry about missing a chance at stupendous gains. That’s what many newsletter ads use to push your buttons, and this latest one for Oxford Club’s Lightning Trend Trader is no exception… how can a red-blooded investor ignore a promise that “303,316% growth kicks off November 1?”

Lightning Trend Trader ($1,495/year these days) has had a couple solid teaser picks over the past year or so in AbbVie (ABBV, teased as “The Genius Molecule”) and Portola (PTLA, pitched as the “Universal Antidote”), though Lichtenfeld has also pitched plenty of stinkers over the years according to our tracking spreadsheets. I have no idea whether that’s indicative of the rest of their portfolio (if you’ve ever tried that newsletter, click here to share your experience with your fellow investors)… so let’s see what he’s hyping this time.

What’s this “Genesis Cure” they’re hinting at? Here are some clues to whet your appetite:

“… one small Boston company just developed a single technology with the potential to eliminate 4,800 rare diseases….

“The MIT Technology Review calls it ‘the biggest biotech discovery of the past century.’

Science magazine reports, ‘The field of biology is now experiencing a transformative phase with the advent of [this technology].'”

And plenty of rosy upside for you:

“All told, I’m projecting you could multiply your money tenfold in the short term… 29-fold in the medium term… and much, much more as this technology sweeps through the $1 trillion rare disease market.

“In other words, you have a very real opportunity here to turn $1,000 into more than $30,000…”

The ad also cites the potential for this “Genesis Cure” to help with Duchenne muscular dystrophy, and cites Dr. Eric Olson at the University of Texas.

And Lichtenfeld goes on to hint at the gene editing technology being teased a bit more:

“This scientist successfully repurposed a naturally occurring enzyme to edit single genes with striking accuracy…

“Suddenly, using this enzyme, doctors could fix the tiny imperfections in genes.

“It has the potential to eliminate the source of virtually EVERY rare disease.

“If your DNA is a blueprint… and a rare disease is just a single bad instruction…

“The Genesis Cure literally erases the bad instruction and replaces it with the right one.

“Every expert who’s taken a serious look at this technology immediately realized it’s the most incredible medical breakthrough since vaccines or even antibiotics.

“The prestigious Nature science journal says it’s like ‘editing out disease.'”

So we can stop there when it comes to big picture — we now know from that that we’re dealing with one of the CRISPR stocks, most of which have been teased and recommended at least a few times by many of the big biotech and technology newsletters — and we’re almost certainly being pointed to one of the triumvirate of publicly traded Cambridge, MA biotechs that claim leadership in gene editing using CRISPR technology (and which, along with other interested parties, are fighting over the patents tooth and claw).

But which one? Is it Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), or Intellia Therapeutics (NTLA)? Let’s check the clues…

“From an investment standpoint, one company behind this technology is on the verge of unprecedented growth.

“Once our brilliant Harvard Ph.D. realized what a revolutionary system she had on her hands…

“She immediately applied for the patents to protect her breakthrough.

“She was the very first person to ever apply for a patent on the Genesis Cure.

“And her company is about to take the $1 trillion rare disease market by storm.”

OK, that pretty well answers the question about “which one” … but let’s check the other clues, just to be sure:

“If you’re looking for the type of biotech that can leap 10-fold in a very short span, this small under-the-radar company is in the perfect position.

“It has just $16 million of revenue… But it’s poised to be the driver of a whole new industry surrounding the Genesis Cure.

“The company is backed by the prestigious University of California, home to a whopping 61 Nobel Prize winners.

“And it holds 19 patents for the Genesis Cure.”

Other hints?

“The company just inked a $293 million deal with pharmaceutical giant Novartis…

“It also made a deal worth $445 million with Regeneron Pharmaceuticals.”

OK, so yes, the Thinkolator can confirm that this is Intellia Therapeutics (NTLA).

What I can’t do is tell you whether it’s going up or not. EDIT, NTLA and CRSP are all moving forward, all actively trying to develop fantastic cures for disease using their variations of CRISPR gene-editing technology, and they’ve all got great partners and plenty of funding and, probably, a long row to hoe before they get to the point where they might actually be selling a product.

This is a gene editing technology, not a drug. It’s not a compound that can alter your body’s chemistry to defeat a disease, or even an antibody that you can either add to your body or inspire with a vaccine to help your body fight off an ailment or infection, it’s a whole new and extremely personalized way of attacking genetic defects or problems, and we’re probably a long way from knowing how it will be commercialized.

That doesn’t mean it’s not worthy of funding or research, of course, or even that investors won’t get rich by backing one or more of these CRISPR horses — it just means there’s not much to the finances of these companies yet, they’re still, despite the vast funding they have available from investors and partners, pretty early-stage R&D projects as far as I can tell. I’m not even really sure what their business model will be — selling a product? A technique? Licensing a technology for other researchers? Charging per cure?

And, of course, there’s the constant legal battle over patents that will be worked out over time, probably benefitting one of these folks over others — most recently it’s been Editas with the upper hand in patent court, but I have no idea what the last word will be.

So I’m left with this… I’ll paraphrase what I wrote to the Irregulars a few weeks back when there was a very similar teaser pitch from Michael Robinson that was hinting at competitor Editas:

If one thing is clear above all others, it’s that I’ve got no personal “edge” to be gained by gaming the decisions of a patent court or judging the relative merits of different highly advanced gene editing technologies… you’ve got to know your limitations. I’m certainly not an expert on any of this stuff, so all I can really tell you is that yes, Marc Lichtenfeld is teasing Intellia (NTLA)… and no, there’s no way the stock price is going to rise tenfold “in the short term.” (Assuming, in this case, that “short term” means a few months or so.)

Beyond that, well, you’re on your own — what do you think? Expect great things ahead for Intellia Therapeutics? Believe that their patents are vastly undervalued? Think other researchers have leapfrogged NTLA with subsequent patents or technologies? Does your brain hurt yet? Let us know with a comment below.


Irregulars Quick Take Paid members get a quick summary of the stocks teased and our thoughts here. Join as a Stock Gumshoe Irregular today (already a member? Log in)

39
Share your thoughts...

avatar
19 Comment threads
20 Thread replies
0 Followers
 
Most reacted comment
Hottest comment thread
34 Comment authors
Cherine YouakimCarl DavisMarktakeprofitsSKB Recent comment authors

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Roger
Member

I know less about beginning biotechs than you. Thusfar Dr. KSS has been incredible in his evaluations of the scientific basis behind each company. Since I don’t have a lifetime to get an MD and PhD, I value whatever he says, and thusfar, I am very happy with all sides of Gumshoe. If it weren’t for his sagacity, I would probably put my savings in an index fund and take up another hobby.

Add a Topic
3932
Archegos
Guest
Archegos

Paul Manpilly is pitching EDIT…so I guess both might be good stocks to buy stock.

Add a Topic
5971
pam day
Guest
pam day

I have been pleased with Oxford Club,as not so much BS,but dont subscribe to this service as so expensive,but you, Travis are so so good with this and always such a superior help!!!

James Hadlock
Guest
James Hadlock

Thanks for your great investigative abilities. I can now sleep nights knowing that ‘The Genesis Cure’ is another ‘possibility’ I can ignore for the short term, and watch for the long term – without the pain of buying another damned newsletter!

Add a Topic
899
Cherine Youakim
Guest
Cherine Youakim

How can Genesis Cure help in Leukemia

Tom
Guest
Tom

I would say Marc Lichtenfeld offered the 300,000% as a long term (retire on) potential if it was applied to all genetic correctable diseases. The pie in the sky. It is then presented as a potential rocket ride based on not too unrealistic market pricing in the near term. Your likely to have a winner if you bet on both, but you will also have a loser. Put them both on a watch and notify list. Maybe a buy stop? You are not alone in wondering what the process is and how it will be rolled out, but I do… Read more »

Add a Topic
655
Add a Topic
947
Tom
Guest
Tom

Correct that to ALNY ,; it went from same ~$20 to $140 in 2.5 yrs before returning to earth. Frankly, I’m not so sure how the market would respond. Clinical trials take years and none are underway.

Karl
Guest
Karl

As I recall Editas has the US patent rights currently, and the other two were able to get the rights to Europe and Asia. I am investing in all three.

Add a Topic
49
Joseph Eastern
Guest

I can’t share any experience with that particular newsletter (I despise $1500/year newsletters in general), but I can share 38 years of experience practicing medicine . After seeing bushels of “miracle cures” come and go, I’ve developed a pretty good bullshit detector. The general rule is this: the broader the claim, the bigger the scam. So anytime you hear about a technology that “could wipe 4800 diseases off the face of the earth”, you don’t need a Thinkolator to figure out – as my dad used to say – that somebody’s pissing on your boots and telling you it’s a… Read more »

Add a Topic
5254
Add a Topic
3042
Add a Topic
3042
thinairmony
Guest

These people who charge unrealistic news letters are for the novice. Running a stock portfolio is not rocket science. And these beggars know this and with say 1 million people who happen to get a e-mail and read t it sounds great. And if these beggars get 10% checks back from the unsuspectingly victim’s it adds up to a nice amount of money. And one day in the future they will pay. Unless they turn from their darkened heart, Truth! $GS!

Add a Topic
5971
Add a Topic
372
bludolphint
Irregular

Good answer! I haven’t heard that expression about raining for quite a while. It made me laugh. Thanks

Arn
Guest
Arn

Since Editas received the patent in the U.S. and won the administrative appellate decision, the Court would normally just defer the final decision to the Patent Officials. In addition, the fact that Editas is advancing and creating a target specific genomic CRISPER system, the issue being appealed in Court will suffer a slow decay of relevance. For the past couple of days, Editas has gained upward momentum with less volatility. A viable fledgling company in Illinois that is being teased by Mr Robinson as a disruptor in the smartphone screen and semiconductor technology. My research indicates that this company’s name… Read more »

Andy
Guest
Andy

Re: Akhan Semiconductor; look to companies such as: Seedinvest, Angel Funding, We Funder, and others like this, but I do not know if Akhan is listed, but I too have heard of Akhan Semiconductor. I have invested via Seedinvest into Mobile Spike and I will be investing a minimum of 2k into Knightscope which closes on Oct. 10th 2017. Every day in the early a.m. hours I see one of Knightscope’s 5′ foot tall units patrolling at California Hospital on Grand Avenue in Los Angeles. Reminds me of the original Lost in Space. Its pretty cool.

Jason
Guest
Jason

You said” this is a gene technology not a drug” Then why are these companies supposedly inking multi million dollar deals with big pharma giants?
Very worrisome. Chances are if any of these gene technologies will replace drugs they will not see the light of day .

Richard Forsythe
Guest
Richard Forsythe

Excellent point Jason but how do we stop it. I agree, it’s very worrisome. The big drug giants may also, by knowing the technology, modify your genetics in certain ways to suit the drugs they peddle, maybe?? This world is getting very technologically advanced but scary.

jbinsc
Member

Yes, Travis, My brain hurts !!!
jbinsc

Albert Eggert
Guest
Albert Eggert

Hi All,
I just want to commend Travis on his Thinkolator and tell him to keep on keeping on your research is invaluable and helps me do my research as well!

Ralph Coffman, Ph.D.
Guest
Ralph Coffman, Ph.D.

In today’s political arena, no cure will ever hit the market place as long as we have a commissioner in the White House who is paid by big Pharmacy. We have had a cure for diabetes for 20 yrs but big pharma will not let it replace the $50 B spent on treating diabetes.

Add a Topic
4154
Add a Topic
4154
Jim
Member

You are so “Right On” Dr. Coffman. And diabetes is not the only one.
I’m still waiting for “the swamp” to be completely drained but I’m not holding my breath.

Add a Topic
4154
D T
Guest
D T

What is the cure for diabetes you claim to know about? Spread the wealth of knowledge you have with those of us that have diabetes.

Add a Topic
4154
Add a Topic
4154
Kenneth Lee
Guest
Kenneth Lee

Dr. Coffman – I’d like to hear more about your cure. Please contact me.

takeprofits
Member

AMEN to that, and you can add CANCER and other modern lifestyle diseases. The medical profession based on pharmaceutical industry propaganda will tell you that type 2 diabetes is incurable, all you can do is control the symptoms with insulin injections or other drugs which is a blatant profit making lie because it is so much more profitable TREATING the disease than it would be CURING it, which is entirely possible without drugs or insulin injections. WHY would they want to actually cure you and thus forfeit the BILLIONS in profit they make keeping you dependant on buying their drugs… Read more »

Add a Topic
3397
Add a Topic
4154
Add a Topic
1358
retepmon
Guest
retepmon

Question for the author: I see you research what other people are trying to sell, but do you ever recommend a stock to buy?. Thanks.

Add a Topic
5971
bludolphint
Irregular

YOU ARE AMAZING TRAVIS!! I just wasted an hour trying to figure out the company. But then… I remembered Stock Gumshoe- and there it was the Genesis cure. Thanks for your investigation. Maybe I’ll come here first next time. Thanks again for your amazing research!

Add a Topic
5971
Andy
Guest
Andy

I thought is Marc was pushing symbol: EDIT or NTLA and the other one that I came up with was JUNO both the name and stock symbol: JUNO. I was leaning toward symbol EDIT because I read Bill Gates was behind part of the funding. You have an excellent history of being correct and you seem to be leaning toward symbol: NTLA.

Add a Topic
5971
Add a Topic
630
john nightingale
Guest
john nightingale

the entire company is a scam and a fraud-I paid supposedly $1495 last night for the “lightning trend trader” but they actually charge me $1995. No point in trying their 888 number no one answers. Basically this so-called Genesis Cure is nothing more than a referral to a company that uses CRISPER as a way to change the DNA of certain molecules. Furthermore never ever become a member of the Oxford club because they will take your money and you’ll get nothing in return. They stop sending me their investment newsletters at least six months ago and I was supposed… Read more »

Add a Topic
366
Julia Guth
Guest

Mr Nightengale, I was dismayed to hear this was your experience with the Club. I show you have been with us since 2004. So I had my team research your account. You ordered Lightning Trend Trader on 9/10. Called on the 11th, and my representative said you only wanted one year for $1495, not 2 yrs for $1995 as you orginally ordered. So they refunded you $500. The Lightning Trend Trader clearly stated no refunds, but they did refund you for the extra year. I see in April of 2016, you were unhappy with some of Steve McDonald’s recommended bonds,… Read more »

Add a Topic
309
Add a Topic
718
Add a Topic
366
Helen
Guest
Helen

John, I beg to differ from your assessment of The Oxford Club. I have been a member for over 2 years and my experience with the club is a positive one. Yes, they are forever pitching new products but it is up to you to do your home work and figure out which direction you want to go. You don’t have to subscribe to every newsletter they send your way.

Add a Topic
366
Mark
Guest
Mark

Hi Helen do you have supper bonds
From the Oxford club and how it works
Thanks let me know

Add a Topic
718
Add a Topic
366
Hugo
Member
Hugo

#John Nightingale

John
I have been a Chairman’s Circle Member of the Oxford Club since the late 1990’s, I have never been disappointed with their service. My experience is quite the opposite of yours. I find their articles timely and well researched by exceedingly smart authors, which gives me a heads up to do my follow up due diligence. Your experience is so very far from mine it is hard to comprehend your criticism.

Wish you the best in the future.

Add a Topic
366
justin williams
Guest
justin williams

I had signed up for a cheaper product with the oxford group and saw they charged me $1,9000. I called and said it was a mistake and they gave me a full refund. I was very surprised that it only took two days to receive the full refund.

Vince DiRe
Guest
Vince DiRe

Is the company they are recommending Crisper and are traded on any stock exchange? Your response is well appreciated. Vince DiRe

Add a Topic
5971
Michael Jorrin,
Author

Some form of CRISPR technology will successfully target A disease – not hundreds or thousands. And some CRISPR outfit will make a mint. But I ain’t young enough to wait. Good luck to those who are!

Add a Topic
5254
Add a Topic
5254
Deb
Guest
Deb

Thanks for all of your insights here for FREE!! I joined Oxford /club about a yr ago and they do have some “inside” tips that have proved to be on the right track-but I hate all of this charging for stuff that is on Google for FREE-if you know where to look-LOL! I love it when they said “Oh, if you had invested in company XYZ back in 2010 your 10,000 would be worth 329,000 today well if it was that simple then all of us would be extremely wealthy! All I know is-if you happen to pick the correct… Read more »

Add a Topic
366
Add a Topic
210
SKB
Guest
SKB

I’ve lost money on anything I’ve ever bought from the hot shots. ‘Nuff said??

Carl Davis
Guest
Carl Davis

Travis/ Marc
As Usual, a Very Good research on the Crispr Technology Stocks. I believe, that we are on the cusp of some astounding Biotechnology medical treatments including gene editing methodology. Because, I couldn’t decipher which of the aforementioned companies were the positive one, I took the Nestea Plunge and went with (ARKG) an ETF that holds All three. Regardless, I believe that all of those companies will SOON be at the forefront of this Positive Technology for all of Mankind !

Add a Topic
4656
Add a Topic
4453